Are Cancer-Screening Blood Tests Close to Prime Time?

Cancer blood tests that detect tiny amounts of tumor DNA in the bloodstream have long promised a simpler way to catch cancer early. While the science has advanced rapidly, recent trial results have tempered expectations about how soon these tests might become routine screening tools.

How Do Multi-Cancer Blood Tests Function?

These tests, often called liquid biopsies, analyze cell-free DNA shed by tumors into the blood. By sequencing this DNA and using algorithms to identify abnormal patterns, the tests aim to signal the presence of cancer and sometimes even suggest where in the body it might be located. The technology has evolved from measuring protein levels to scrutinizing genetic fragments, enabling detection of multiple cancer types from a single blood draw.

What Did the Largest Trial to Date Find?

The most significant study to evaluate a multi-cancer blood test was conducted by Grail, the biotechnology company behind the Galleri test, which claims to detect more than 50 cancer types. Published in 2024, the trial did not meet its primary objective of showing a significant reduction in advanced cancer diagnoses among those who received the test compared to those who did not. Despite this outcome, researchers note that the test demonstrated an ability to detect various cancers, including some at early stages, though not with sufficient impact to change screening outcomes in the study population.

Are There Other Promising Blood Tests in Development?

Yes, several companies are advancing blood-based screening for specific cancers. For example, Guardant Health’s Shield test, designed to screen for colorectal cancer, showed 83% effectiveness in detecting colorectal cancers in a study published in the New England Journal of Medicine. Experts suggest such tests could improve screening rates by offering a less invasive alternative to colonoscopies, though they would not replace the gold-standard procedure for those who can undergo it.

What Are the Current Limitations?

While exciting, these tests are not yet perfect. False positives and false negatives remain concerns, meaning a positive result does not always confirm cancer and a negative result does not completely rule it out. Most tests are not yet FDA-approved for general population screening and are often available only through healthcare providers or under specific programs. Cost, accessibility, and the need for further validation in diverse populations also pose challenges.

What’s Next for Cancer Blood Testing?

Research continues to refine the accuracy of these tests and determine how they might best be used—whether as supplements to existing screening methods or, eventually, as standalone tools for certain cancers. Ongoing trials and real-world studies will help clarify their role in reducing cancer mortality. For now, experts view multi-cancer blood tests as promising but not yet ready to replace established screening guidelines.

Key Takeaways

• Multi-cancer blood tests detect tumor DNA in the blood to screen for multiple cancer types.
• The largest trial of Grail’s Galleri test did not display a significant reduction in advanced cancer diagnoses.
• Other blood tests, like Guardant Health’s Shield for colorectal cancer, show promise for specific cancers.
• Tests are not yet perfect and face limitations including accuracy, cost, and availability.
• Further research is needed before these tools can be widely recommended for routine screening.

Frequently Asked Questions

Can a blood test replace a colonoscopy or mammogram?

Not currently. Blood-based screening tests are being studied as potential complements to, not replacements for, established screening methods like colonoscopy and mammography.

Are these tests available to the public?

Some tests, such as Galleri, are available by prescription through healthcare providers but are not yet FDA-approved for general screening use in the United States.

Do these tests detect all cancers?

No test currently detects all cancers. Multi-cancer tests aim to screen for many types, but sensitivity varies by cancer type and stage.

Is a positive result a cancer diagnosis?

No. A positive result indicates the need for follow-up diagnostic testing, such as imaging or biopsy, to confirm whether cancer is present.